Diego Malon Gimenez
@diegomalon.bsky.social
Medical oncologist at Dr. George L. Dumont University Hospital (breast, melanoma, lung) Moncton (NB) trained at Princess Margaret CC Toronto.
Reposted by Diego Malon Gimenez
Are tumor pathogenic variants in #BRCA associated with the response to deescalated neoadjuvant nab-paclitaxel plus either carboplatin or gemcitabine among patients with early-stage triple-negative #breastcancer? @jama.com
#bcsm #hereditarycancer #womenshealth #oncsky #cancerresearch
#bcsm #hereditarycancer #womenshealth #oncsky #cancerresearch
Genetic Alterations, Response, and Survival in Triple-Negative Breast Cancer
This secondary analysis of a randomized clinical trial compares deescalated neoadjuvant regimens of nab-paclitaxel plus either carboplatin or gemcitabine to examine the effects of BRCA1 and/or BRCA2 t...
jamanetwork.com
April 24, 2025 at 2:20 PM
Are tumor pathogenic variants in #BRCA associated with the response to deescalated neoadjuvant nab-paclitaxel plus either carboplatin or gemcitabine among patients with early-stage triple-negative #breastcancer? @jama.com
#bcsm #hereditarycancer #womenshealth #oncsky #cancerresearch
#bcsm #hereditarycancer #womenshealth #oncsky #cancerresearch
Reposted by Diego Malon Gimenez
(Me flirting) Did you know microbes in the human body contribute MORE to the human body’s survival than our bodies themselves? And there are more microbial genes than human in our bodies?
We just big ol’ walkin’ terrariums.
The sauce:
www.nih.gov/news-events/...
We just big ol’ walkin’ terrariums.
The sauce:
www.nih.gov/news-events/...
NIH Human Microbiome Project defines normal bacterial makeup of the body
Genome sequencing creates first reference data for microbes living with healthy adults.
www.nih.gov
March 16, 2025 at 5:48 AM
(Me flirting) Did you know microbes in the human body contribute MORE to the human body’s survival than our bodies themselves? And there are more microbial genes than human in our bodies?
We just big ol’ walkin’ terrariums.
The sauce:
www.nih.gov/news-events/...
We just big ol’ walkin’ terrariums.
The sauce:
www.nih.gov/news-events/...
Reposted by Diego Malon Gimenez
Study evaluated the efficacy of cryotherapy combined with taxane infusion in preventing peripheral neuropathy (PN) in #BreastCancer patients receiving paclitaxel or nab-paclitaxel.
https://buff.ly/3PIMO1P
https://buff.ly/3PIMO1P
January 21, 2025 at 12:21 PM
Study evaluated the efficacy of cryotherapy combined with taxane infusion in preventing peripheral neuropathy (PN) in #BreastCancer patients receiving paclitaxel or nab-paclitaxel.
https://buff.ly/3PIMO1P
https://buff.ly/3PIMO1P
Reposted by Diego Malon Gimenez
#SABCS24 #bcsm #OncSky
Dr. J O’Shaughnessy presents prespecified exploratory biomarker analysis of KN522 trial of pembro in #breastcancer
See pics ⬇️ for conclusions & link or QR code for full results:
bit.ly/3CejYmo
@oncoalert.bsky.social
Dr. J O’Shaughnessy presents prespecified exploratory biomarker analysis of KN522 trial of pembro in #breastcancer
See pics ⬇️ for conclusions & link or QR code for full results:
bit.ly/3CejYmo
@oncoalert.bsky.social
December 11, 2024 at 12:58 AM
#SABCS24 #bcsm #OncSky
Dr. J O’Shaughnessy presents prespecified exploratory biomarker analysis of KN522 trial of pembro in #breastcancer
See pics ⬇️ for conclusions & link or QR code for full results:
bit.ly/3CejYmo
@oncoalert.bsky.social
Dr. J O’Shaughnessy presents prespecified exploratory biomarker analysis of KN522 trial of pembro in #breastcancer
See pics ⬇️ for conclusions & link or QR code for full results:
bit.ly/3CejYmo
@oncoalert.bsky.social
Reposted by Diego Malon Gimenez
EMBER3 now in @NEJM highlights imlunestrant is better than fulvestrant in mESR1 MBC, and combo of abema+ imlumnestrant is better independent of mutations in all
Presentation soon @sabcs.bsky.social #SABCS24 Congrats @breastcancerdoc.bsky.social et al!
www.nejm.org/doi/full/10....
Presentation soon @sabcs.bsky.social #SABCS24 Congrats @breastcancerdoc.bsky.social et al!
www.nejm.org/doi/full/10....
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer | NEJM
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor
(ER) degrader that delivers continuous ER inhibition, even in cancers with mutations
in the gene encoding ERα (E...
www.nejm.org
December 11, 2024 at 2:46 PM
EMBER3 now in @NEJM highlights imlunestrant is better than fulvestrant in mESR1 MBC, and combo of abema+ imlumnestrant is better independent of mutations in all
Presentation soon @sabcs.bsky.social #SABCS24 Congrats @breastcancerdoc.bsky.social et al!
www.nejm.org/doi/full/10....
Presentation soon @sabcs.bsky.social #SABCS24 Congrats @breastcancerdoc.bsky.social et al!
www.nejm.org/doi/full/10....
Reposted by Diego Malon Gimenez
Great slide highlighting not only are TILs predictive of pCR...it also translates to being prognostic beyond pCR for good outcome and DFS.
Seems like we have a LOT of data on TILs now, why aren't they standardly provided on path reports???🧐
#SABCS24
@oncoalert.bsky.social
@sabcs.bsky.social
Seems like we have a LOT of data on TILs now, why aren't they standardly provided on path reports???🧐
#SABCS24
@oncoalert.bsky.social
@sabcs.bsky.social
December 11, 2024 at 2:04 PM
Great slide highlighting not only are TILs predictive of pCR...it also translates to being prognostic beyond pCR for good outcome and DFS.
Seems like we have a LOT of data on TILs now, why aren't they standardly provided on path reports???🧐
#SABCS24
@oncoalert.bsky.social
@sabcs.bsky.social
Seems like we have a LOT of data on TILs now, why aren't they standardly provided on path reports???🧐
#SABCS24
@oncoalert.bsky.social
@sabcs.bsky.social
Reposted by Diego Malon Gimenez
#SABCS24 Day 1 Highlights #CommunityOnc:
1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib
2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L
3. #DB06: HR+ TDXd
4. #KN522: biomarker analysis
#OncSky #CanSky @sabcs.bsky.social @drsarahsammons.bsky.social @dr-rshatsky.bsky.social
1/5
1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib
2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L
3. #DB06: HR+ TDXd
4. #KN522: biomarker analysis
#OncSky #CanSky @sabcs.bsky.social @drsarahsammons.bsky.social @dr-rshatsky.bsky.social
1/5
December 11, 2024 at 2:26 AM
#SABCS24 Day 1 Highlights #CommunityOnc:
1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib
2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L
3. #DB06: HR+ TDXd
4. #KN522: biomarker analysis
#OncSky #CanSky @sabcs.bsky.social @drsarahsammons.bsky.social @dr-rshatsky.bsky.social
1/5
1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib
2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L
3. #DB06: HR+ TDXd
4. #KN522: biomarker analysis
#OncSky #CanSky @sabcs.bsky.social @drsarahsammons.bsky.social @dr-rshatsky.bsky.social
1/5
Reposted by Diego Malon Gimenez
#EMBER3
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
December 11, 2024 at 3:27 PM
#EMBER3
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Imlunestrant (oral SERD) beats fulv (88% of SOC ET) in 2nd line ER+ #bcsm only in those with ESR1 mut
However, combo of Imlunestrant + abema wins in all-comers 5.5 vs. 9.5 mo regardless of ESR1
* note prior CDK not required
#SABCS24
@sabcs.bsky.social
@oncoalert.bsky.social
Reposted by Diego Malon Gimenez
#SABCS24 #bcsm #OncSky
We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky
@oncoalert.bsky.social
We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky
@oncoalert.bsky.social
December 10, 2024 at 11:54 PM
#SABCS24 #bcsm #OncSky
We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky
@oncoalert.bsky.social
We need to ask all patients on endocrine therapy for #breastcancer about vaginal dryness & sexual dysfunction. Here’s a useful stepwise approach to managing these issues from
@JenniShengMD. #MedSky
@oncoalert.bsky.social
Reposted by Diego Malon Gimenez
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
December 13, 2024 at 8:08 PM
Wrapping up another fantastic #SABCS!
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Amazing, practice-changing data were presented.
I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease!
#SABCS24 @oncoalert.bsky.social
Reposted by Diego Malon Gimenez
Presented at #SABCS24:
The INSEMA randomized trial involving patients with clinically node-negative, T1 breast cancer showed that the omission of axillary surgery was noninferior to sentinel-lymph-node biopsy. Full trial results: nej.md/41o5L0Z
#MedSky
The INSEMA randomized trial involving patients with clinically node-negative, T1 breast cancer showed that the omission of axillary surgery was noninferior to sentinel-lymph-node biopsy. Full trial results: nej.md/41o5L0Z
#MedSky
Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial | NEJM
Whether surgical axillary staging as part of breast-conserving therapy can be omitted
without compromising survival has remained unclear. In this prospective, randomized,
noninferiority trial, we i...
nej.md
December 12, 2024 at 3:14 PM
Presented at #SABCS24:
The INSEMA randomized trial involving patients with clinically node-negative, T1 breast cancer showed that the omission of axillary surgery was noninferior to sentinel-lymph-node biopsy. Full trial results: nej.md/41o5L0Z
#MedSky
The INSEMA randomized trial involving patients with clinically node-negative, T1 breast cancer showed that the omission of axillary surgery was noninferior to sentinel-lymph-node biopsy. Full trial results: nej.md/41o5L0Z
#MedSky
Reposted by Diego Malon Gimenez
10 year follow up on OlympiA shows persistent benefit in iDFS, OS. #SABCS24 @oncoalert.bsky.social
December 11, 2024 at 5:30 PM
10 year follow up on OlympiA shows persistent benefit in iDFS, OS. #SABCS24 @oncoalert.bsky.social
Reposted by Diego Malon Gimenez
#SABCS24 #bcsm #OncSky #SurgSky #MedSky
📣 INSEMA Trial
Omission of sentinel node biopsy (SLNB) in pts w/ clin node-neg early #breastcancer did not result in inferior IDFS (@ 6 yrs: 91.7 vs 91.9%).
Suggests no SLNB may be👌 for age 50+ w/ gr 1-2, ER+/HER2- tumors, up to 2 cm
@oncoalert.bsky.social
📣 INSEMA Trial
Omission of sentinel node biopsy (SLNB) in pts w/ clin node-neg early #breastcancer did not result in inferior IDFS (@ 6 yrs: 91.7 vs 91.9%).
Suggests no SLNB may be👌 for age 50+ w/ gr 1-2, ER+/HER2- tumors, up to 2 cm
@oncoalert.bsky.social
December 12, 2024 at 5:02 PM
#SABCS24 #bcsm #OncSky #SurgSky #MedSky
📣 INSEMA Trial
Omission of sentinel node biopsy (SLNB) in pts w/ clin node-neg early #breastcancer did not result in inferior IDFS (@ 6 yrs: 91.7 vs 91.9%).
Suggests no SLNB may be👌 for age 50+ w/ gr 1-2, ER+/HER2- tumors, up to 2 cm
@oncoalert.bsky.social
📣 INSEMA Trial
Omission of sentinel node biopsy (SLNB) in pts w/ clin node-neg early #breastcancer did not result in inferior IDFS (@ 6 yrs: 91.7 vs 91.9%).
Suggests no SLNB may be👌 for age 50+ w/ gr 1-2, ER+/HER2- tumors, up to 2 cm
@oncoalert.bsky.social
Reposted by Diego Malon Gimenez
Padma trial confirms that no role of chemo in first line chemo in HR+ HER2- MBC. Great data. #sabcs24. @sabcs.bsky.social
December 11, 2024 at 12:26 AM
Padma trial confirms that no role of chemo in first line chemo in HR+ HER2- MBC. Great data. #sabcs24. @sabcs.bsky.social
Reposted by Diego Malon Gimenez
1. Recent #FDA approvals:
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
December 11, 2024 at 2:26 AM
1. Recent #FDA approvals:
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
a). #NATALEE: Adj #Ribociclib in HR+ Stg IIA - III, 400mg 3wks on, 1wk off for 3yrs. 3yr iDFS 90.7% vs 87.6, 3.1% absolute iDFS
b). #INAVO120: Inavolisib + Fulvestrant + Palbo vs Palbo/Fulvestrant HR+ mBC. PFS 15.0 vs 7.3mos (HR 0.43)
2/5
Reposted by Diego Malon Gimenez
4. #KN522: current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC.
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
December 11, 2024 at 2:26 AM
4. #KN522: current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC.
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.
5/5
Reposted by Diego Malon Gimenez
3. #DB06: . DestinyBreast06: Ph III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow
- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??
4/5
- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??
4/5
December 11, 2024 at 2:26 AM
3. #DB06: . DestinyBreast06: Ph III, TDXd vs chemo in endocrine resistant HR+ HER2 low and HER2-ultralow
- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??
4/5
- Improved PFS regardless of time to progression on CDK4/6i or tumor burden
- PFS2 better w/ TDXd
- In what line will you use this??
4/5
Reposted by Diego Malon Gimenez
2. #PADMA: Ph III, HR+ metastatic breast cancer, chemo vs ET + Palbociclib.
- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.
- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3/5
- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.
- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3/5
December 11, 2024 at 2:26 AM
2. #PADMA: Ph III, HR+ metastatic breast cancer, chemo vs ET + Palbociclib.
- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.
- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3/5
- #SABCS22 in #RightChoice study, we knew CDK4/6i upfront is better.
- Time to treatment failure and PFS better in PADMA. CDK4/6i remain 1L SoC for these pts
3/5
Reposted by Diego Malon Gimenez
Full trial report here - www.thelancet.com/journals/lan...
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO trial)
#OncSky #MedSky
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO trial)
#OncSky #MedSky
November 26, 2024 at 7:21 AM
Full trial report here - www.thelancet.com/journals/lan...
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO trial)
#OncSky #MedSky
Molecularly guided therapy versus chemotherapy after disease control in unfavourable cancer of unknown primary (CUPISCO trial)
#OncSky #MedSky
Reposted by Diego Malon Gimenez
Unraveling lipid metabolism for acute myeloid leukemia... : Current Opinion in Hematology 🧪
journals.lww.com/co-hematolog...
journals.lww.com/co-hematolog...
Unraveling lipid metabolism for acute myeloid leukemia... : Current Opinion in Hematology
man leukemia, particularly highlighting work in leukemic stem cells (LSCs), where lipids were assessed directly as a metabolite.
Recent findings
Lipid metabolism is essential to support LSC functio...
journals.lww.com
November 26, 2024 at 9:16 AM
Unraveling lipid metabolism for acute myeloid leukemia... : Current Opinion in Hematology 🧪
journals.lww.com/co-hematolog...
journals.lww.com/co-hematolog...
Reposted by Diego Malon Gimenez
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!
November 17, 2024 at 8:01 PM
Only 3 weeks to #SABCS24, a meeting that promises to significantly impact the way we treat breast cancer. It will feature phase 3 data with novel SERDs, novel ADCs, immunotherapy, ctDNA monitoring, important biomarker analyses & so much more. Here’s my top 10 abstracts list— see you in San Antonio!